DW Healthcare runs process to extend hold over animal pharmaceuticals business

While some participants have described secondaries activity as somewhat subdued in the early part of the year, numerous deals continue to work through their processes that had been launched last year.

SECONDARIES INVESTOR

Register to unlock this content

• Daily global secondaries market news and intelligence
• Curated insights to keep you ahead of GP-led and LP-led secondaries
• Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
• Access to proprietary research and reports
• Selected fund performance and investor activity data

Register nowFind out more

DealsNorth AmericaSecondariesSingle AssetsGP-Leds